
Prologis, Teledyne Technologies, Hamilton Lane, Ascendis Pharma A/S, Tyra Biosciences, Canopy Growth, and Trinity Capital are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares in companies expected to grow revenue and earnings faster than the overall market, often driven by expanding markets, innovation, or strong competitive advantages. Investors buy them for capital appreciation rather than income, and they typically reinvest profits, trade at higher valuations, and carry higher volatility and risk. These companies had the highest dollar trading volume of any Growth stocks within the last several days.
Prologis (PLD)
Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2024, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries.
Teledyne Technologies (TDY)
Teledyne Technologies Incorporated, together with its subsidiaries, provides enabling technologies for industrial growth markets in the United States and internationally. Its Digital Imaging segment provides visible spectrum sensors and digital cameras; and infrared, ultraviolet, visible, and X-ray spectra; as well as micro electromechanical systems and semiconductors, including analog-to-digital and digital-to-analog converters.
Read Our Latest Research Report on TDY
Hamilton Lane (HLNE)
Hamilton Lane Incorporated is a private equity firm specializing in early venture, emerging growth, turnaround, middle market, mature, mid-venture, bridge, buyout, distressed/vulture, loan, mezzanine in growth capital companies. It prefers to invest in energy, industrials, consumer discretionary, health care, real estate, information technology, utilities, and consumer services.
Read Our Latest Research Report on HLNE
Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Read Our Latest Research Report on ASND
Tyra Biosciences (TYRA)
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Read Our Latest Research Report on TYRA
Canopy Growth (CGC)
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments.
Read Our Latest Research Report on CGC
Trinity Capital (TRIN)
Read Our Latest Research Report on TRIN
Featured Articles
- MarketBeat’s Top Five Stocks to Own in January 2026
- 5 Stocks Retail Investors Are Betting on for 2026
- 2025’s Most Upgraded Stocks—And What 2026 Might Hold
- These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
- These 3 Turnaround Contenders Could Be Set for a Big 2026 Break
- 3 AI and Cloud Stocks With Analyst Conviction and Long Runways
